Cervical Cancer

Approval of the self-collection solution may reduce barriers to sample collection and increase access to cervical cancer screening.

The CheckMate 358 trial assessed various doses of nivolumab with or without ipilimumab for recurrent or metastatic cervical cancer.

Tisotumab vedotin-tftv may now be given to patients with recurrent or metastatic cervical cancer, according to the FDA.

Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.

A phase 2 trial showed favorable antitumor activity when tislelizumab plus chemotherapy was used for patients with locally advaned cervical cancer.

Study finds social determinants of health linked to variations in cervical cancer rates.

Treatment with simple hysterectomy reduces the incidence of urinary incontinence compared with radical hysterectomy in patients with low-risk cervical cancer.

Tisotumab vedotin may become the first antibody drug conjugate to receive marketing authorization in the European Union as a treatment for those with cervical cancer.

Treatment with pembrolizumab plus chemotherapy with or without bevacizumab yields an overall survival improvement regardless of squamous or nonsquamous cervical cancer histology.

The FDA approval of pembrolizumab plus chemoradiation benefits patients with stage III to IVA cervical cancer based on findings from the KEYNOTE-A18 trial, according to Jyoti S. Mayadev, MD.

Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.

Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.

Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.

Findings from the phase 3 KEYNOTE-A18 trial support the FDA approval of pembrolizumab plus external beam radiotherapy and concurrent chemotherapy in stage III to IVA cervical cancer.

The FDA has set a Prescription Drug User Fee Act date of May 9, 2024 for the potential full approval of tisotumab vedotin for those with recurrent or metastatic cervical cancer.

Ritu Salani, MD, suggests using the immune system to find treatment options for cervical cancer is the logical course of action.

Despite the addition of a TIGIT inhibitor to a checkpoint inhibitor resulting in high levels of safety, there is no future for that combination alone, according to Ritu Salani, MD.

The addition of a TIGIT inhibitor to a checkpoint inhibitor showed numerical improvement but did not show statistical significance in patients with recurrent cervical cancer, according to Ritu Salani, MD.

Investigators note a trend towards improved overall survival with cadonilimab plus chemotherapy with or without bevacizumab among those with cervical cancer in the phase 3 AK104-303 trial.

Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.

Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.

Findings from the phase 2 SKYSCRAPER-04 trial support dual targeting of TIGIT and PD-L1 in patients with PD-L1–positive cervical cancer, says Ritu Salani, MD.

Results from the phase 3 GCIG INTERLACE trial highlight progression-free survival and overall survival improvements with induction chemotherapy plus chemoradiotherapy for patients with locally advanced cervical cancer.

Radical hysterectomies result in worse symptom experience, body image, menopausal symptoms, sexual worry, sex activity and enjoyment compared with simple hysterectomy in those with early-stage cervical cancer.

Progression-free survival benefit appears consistent in patients with recurrent or metastatic cervical cancer treated with tisotumab vedotin.